| First Author | Nishino H | Year | 1999 |
| Journal | Anticancer Res | Volume | 19 |
| Issue | 5A | Pages | 3663-4 |
| PubMed ID | 10625935 | Mgi Jnum | J:60031 |
| Mgi Id | MGI:1352550 | Citation | Nishino H, et al. (1999) Suppression of lung and liver carcinogenesis in mice by oral administration of myo-inositol. Anticancer Res 19(5A):3663-4 |
| abstractText | It has been reported that myo-inositol can inhibit carcinogenesis in various organs, such as the mammary gland, colon and lung. In the present study, at first, inhibitory effects of myo-inositol on lung carcinogenesis were confirmed. Then, the influence of myo-inositol on liver carcinogenesis in mice was investigated. In C3H/He male mice, the rate of spontaneous liver carcinogenesis is known to be high. Using this experimental model, the effects of oral administration of myo-inositol (added into the drinking water at the concentration of 1%) were assessed. Significant suppression of liver carcinogenesis was observed in mice treated with myo-inositol for 40 weeks. In the control group without myo-inositol administration, 88% of the animals developed liver tumors, whereas in the myo-inositol-supplemented group, the incidence of liver tumors was 38% (p < 0.05). The average number of liver tumors per mouse was also decreased significantly by myo-inositol treatment; from 7.8 in the control group to 0.8 in the myo-inositol-supplemented group (p < 0.01). Thus, myo-inositol may be useful for cancer chemoprevention in the liver, as well as the lung. |
